Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.
about
HIV-1 integrase inhibitor resistance and its clinical implicationsDolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIVResistance against Integrase Strand Transfer Inhibitors and Relevance to HIV PersistenceShould we treat acute HIV infection?Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failureCombination therapies for combating antimicrobial resistanceImpact of baseline HIV-1 RNA levels on initial highly active antiretroviral therapy outcome: a meta-analysis of 12,370 patients in 21 clinical trials*Long-term efficacy and safety of raltegravir in the management of HIV infection.Efavirenz-Based Regimens in Antiretroviral-Naive HIV-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsThe effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trialHIV quasispecies dynamics during pro-active treatment switching: impact on multi-drug resistance and resistance archiving in latent reservoirsDevelopment of elvitegravir resistance and linkage of integrase inhibitor mutations with protease and reverse transcriptase resistance mutationsClinical use of HIV integrase inhibitors: a systematic review and meta-analysisResistance mutations outside the integrase coding region have an effect on human immunodeficiency virus replicative fitness but do not affect its susceptibility to integrase strand transfer inhibitorsThe Global Health Impact Index: Promoting Global HealthTherapy-Emergent Drug Resistance to Integrase Strand Transfer Inhibitors in HIV-1 Patients: A Subgroup Meta-Analysis of Clinical TrialsChallenges in initiating antiretroviral therapy in 2010.What's new for antiretroviral treatment in women with HIVSystems pharmacology uncovers Janus functions of botanical drugs: activation of host defense system and inhibition of influenza virus replication.New therapeutic landscape of NNRTIs for treatment of HIV: a look at recent data.Risk of Acute Liver Injury With Antiretroviral Therapy by Viral Hepatitis Status.High concentration of raltegravir in semen of HIV-infected men: results from a substudy of the EASIER-ANRS 138 trial.Influence of Sex/Gender and Race on Responses to Raltegravir Combined With Tenofovir-Emtricitabine in Treatment-Naive Human Immunodeficiency Virus-1 Infected Patients: Pooled Analyses of the STARTMRK and QDMRK Studies.Clinical Improvement by Switching to an Integrase Strand Transfer Inhibitor in Hemophiliac Patients with HIV: The Japan Cohort Study of HIV Patients Infected through Blood ProductsUrinary eicosanoid metabolites in HIV-infected women with central obesity switching to raltegravir: an analysis from the women, integrase, and fat accumulation trial.Early virologic response to abacavir/lamivudine and tenofovir/emtricitabine during ACTG A5202.French 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults.Novel approaches to HIV therapy.Biochemical and pharmacological analyses of HIV-1 integrase flexible loop mutants resistant to raltegravirEffects of switching from efavirenz to raltegravir on endothelial function, bone mineral metabolism, inflammation, and renal function: a randomized, controlled trial.Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.Similar efficacy and tolerability of raltegravir-based antiretroviral therapy in HIV-infected patients, irrespective of age group, burden of comorbidities and concomitant medication: Real-life analysis of the German 'WIP' cohort.Recent key advances in human immunodeficiency virus medicine and implications for ChinaSimilar efficacy of raltegravir when used with or without a protease inhibitor in treatment-experienced patients.Cobicistat: a Novel Pharmacoenhancer for Co-Formulation with HIV Protease and Integrase InhibitorsEfficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial.Resistance analyses of integrase strand transfer inhibitors within phase 3 clinical trials of treatment-naive patients.Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment-naïve, HIV-1-infected patients at 48 weeks.Resistance to integrase inhibitors.Rate and determinants of treatment response to different antiretroviral combination strategies in subjects presenting at HIV-1 diagnosis with advanced disease
P2860
Q24628743-A9560856-ED7B-4A15-88A2-C526C50C013FQ26799712-B49F7056-7BB9-46B2-A23F-2BC2A5F3C929Q26801286-0000E759-7458-47E6-9EB2-2F338DE139D4Q26826523-E5460FB6-170F-4BFB-820E-1501A7684C0EQ27003431-4F2BCA40-2B7A-47B1-8F49-84F4C9955AE2Q27015710-D629C6B2-98EF-40A1-AB02-D699424BCCADQ27015850-85A75213-DB72-4BB8-ACD7-A5B3A9FA5649Q27686870-15346088-ACC3-41FE-8C16-C01D10B465B3Q28081266-6C9C1840-860F-422A-BCEF-55E824683D5EQ28475076-73107DEF-DACC-487F-A49A-4587F848E2F6Q28477500-4CE77A96-F73A-4C62-B1F2-2CF73A47B134Q28481393-B4F20473-8A0B-4EFA-A735-1A9AEFE5489BQ28484930-933256FD-C4F5-4E57-8887-C9B304D68D42Q28533830-4702DBF4-F7EB-445C-97DC-8074367148C9Q28551476-E1DFD1ED-D586-4A05-AD8A-7C8A00D6D215Q28553571-D960B79E-0A52-4339-943A-BAFD0F8B3571Q30227046-781827E7-4C8A-4B3F-A8B6-57A8278EABD6Q30391322-5ADE6463-A275-461F-919A-8BABB2ADC0F9Q30423829-CE0F72EE-443D-417D-A8B5-765B9C9A11A0Q30578338-0C853748-CF82-4D3D-92DC-DC34DB78DE76Q33609481-D6CB6A2B-8CF4-45B8-B28F-49C77C26490FQ33613775-D722F3D0-1852-468F-989C-01968D1542F4Q33629439-765AD4FD-C73A-4AF0-B501-4B6A7B2849D5Q33668385-95618FCB-3AC7-49EA-9365-56F111CEFE65Q33759853-3DFD855C-5432-4E96-85EE-AB2222EFED6FQ33767281-65BF9C91-9824-42BC-8B85-CEAF81798D08Q33775397-EC46A2BF-14DD-4A2C-A44E-744DA9561C1CQ33777819-8039E810-8A15-4A54-BBE7-E5BD61CDEF94Q33838063-67F22D9B-287E-4370-A9D2-27DBABAB4A4CQ33880418-5EE18A70-4BF7-44F5-88E5-0FA1BA1C35BDQ33909996-D282E75A-3EDD-4FB7-9A49-77A48E4A476DQ33910849-AD81B289-D2CF-43B0-9302-3FCAE2E03D50Q33933502-96BEC362-EA4D-4A99-AE6E-D52493A08EFBQ33935930-97B53C35-21DF-4CC0-9C7C-71AC3D5B925EQ33939069-FEB0AA72-A0F9-4DE6-8F66-D4FE97830572Q33945171-26003B14-7E19-4D80-9BA4-C7AA2557F1C9Q33963458-FC998052-4F9F-452E-BE38-A47794085043Q34035045-A789A6B5-85EB-4AE9-8CED-C7A8E788448FQ34059896-902D356E-70C7-47EE-A979-0FFF8F7E0C0AQ34100037-5CD08EEA-C4D7-4398-9E90-3BDEBF5DA2CE
P2860
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Safety and efficacy of raltegr ...... d randomised controlled trial.
@en
Safety and efficacy of raltegr ...... d randomised controlled trial.
@nl
type
label
Safety and efficacy of raltegr ...... d randomised controlled trial.
@en
Safety and efficacy of raltegr ...... d randomised controlled trial.
@nl
prefLabel
Safety and efficacy of raltegr ...... d randomised controlled trial.
@en
Safety and efficacy of raltegr ...... d randomised controlled trial.
@nl
P2093
P1433
P1476
Safety and efficacy of raltegr ...... d randomised controlled trial.
@en
P2093
Angela Williams-Diaz
Anthony J Rodgers
Bach-Yen Nguyen
Daniel S Berger
Edwin DeJesus
Jeffrey L Lennox
Jose Valdez Ramalho Madruga
Mark J DiNubile
Michael D Miller
P304
P356
10.1016/S0140-6736(09)60918-1
P407
P577
2009-08-03T00:00:00Z